Who are Autologous PRP's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Low-dose PRP, Leukocyte rich platelet rich plasma, Platelet Rich Plasma (PRP), Autologous platelets rich plasma, The platelet rich plasma（PRP）.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/autologous-prp.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Autologous PRP — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Autologous PRP (Autologous PRP) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Autologous cell therapy / Regenerative medicine. Area: Regenerative Medicine / Orthopedics / Wound Healing.

phase 3 Autologous cell therapy / Regenerative medicine Regenerative Medicine / Orthopedics / Wound Healing Biologic Live · refreshed every 30 min

Target snapshot

Autologous PRP (Autologous PRP) — Iffat Anwar Medical Complex. Autologous platelet-rich plasma (PRP) delivers concentrated growth factors and cytokines from the patient's own blood to promote tissue repair and regeneration.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
Autologous PRP TARGET	Autologous PRP	Iffat Anwar Medical Complex	phase 3	Autologous cell therapy / Regenerative medicine
Low-dose PRP	Low-dose PRP	Hospital for Special Surgery, New York	marketed	Autologous cell therapy / Regenerative medicine product
Leukocyte rich platelet rich plasma	Leukocyte rich platelet rich plasma	University Hospitals Cleveland Medical Center	marketed	Autologous cell therapy / Regenerative medicine product
Platelet Rich Plasma (PRP)	Platelet Rich Plasma (PRP)	Aspetar	marketed	Autologous cell therapy / Regenerative medicine
Autologous platelets rich plasma	Autologous platelets rich plasma	Mostafa Hassanein, Msc	marketed	Autologous cell therapy / Regenerative medicine product
The platelet rich plasma（PRP）	The platelet rich plasma（PRP）	Peking University Third Hospital	phase 3	Autologous cell therapy / Regenerative medicine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Autologous cell therapy / Regenerative medicine class)

Aspetar · 1 drug in this class
Iffat Anwar Medical Complex · 1 drug in this class
Peking University Third Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Autologous PRP — Competitive Intelligence Brief. https://druglandscape.com/ci/autologous-prp. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing